Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.76 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.76 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497088 | 1.00 | SLC29A1 (0.78) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9033402 | 0.92 | TSHR (0.78) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9033409 | 0.92 | TSHR (0.78) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL640593 | 0.90 | SLC29A1 (0.77) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29463998 | 0.90 | SLC29A1 (0.77) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL640594 | 0.90 | SLC29A1 (0.77) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL639285 | 0.89 | SLC29A1 (0.77) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL639284 | 0.89 | SLC29A1 (0.77) | SLC29A1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL17825968 | 0.88 | SLC29A1 (1.00) | SLC29A1ADORA3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL20626394 | 0.88 | SLC29A1 (1.00) | SLC29A1ADORA3PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1778712-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1746885-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | disclosed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | SLC29A1 257/4885ADORA3 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.